16 completed. 16 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 6 | Completed 6 |
Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of INI-4001 in Patients With Advanced Solid Tumours INI-4001, Nivolumab, Pembrolizumab - Advanced Solid Tumor | Phase 1 | Completed | Inimmune Corporation | 10 | 2024-07-01 | 2026-10-16 |
| Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) M1774, Cemiplimab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 61 | 2023-09-13 | 2026-09-14 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| ASP8374 + Cemiplimab in Recurrent Glioma ASP8374, cemiplimab - Glioblastoma, Recurrent Glioblastoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 14 | 2022-03-09 | 2025-10-22 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer Cemiplimab, Capecitabine - Hormone Receptor-positive Breast Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 13 | 2021-10-12 | 2026-07-02 |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-03 | 2025-04-23 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Cemiplimab - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 97 | 2019-04-11 | 2026-01-21 |
| A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab - Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | SillaJen, Inc. | 95 | 2018-06-19 | 2026-06-18 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Isatuximab SAR650984, Cemiplimab REGN2810 - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Sanofi | 109 | 2018-02-21 | 2024-06-14 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) REGN2810 - Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck | Phase 1 | Completed | Regeneron Pharmaceuticals | 33 | 2017-07-03 | 2020-03-19 |
| A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors SAR439459, Cemiplimab REGN2810 - Malignant Solid Tumor | Phase 1 | Completed | Sanofi | 161 | 2017-06-09 | 2024-08-07 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) REGN2810 - Melanoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 47 | 2017-04-10 | 2020-04-20 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers REGN3767, cemiplimab - Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 333 | 2016-11-07 | 2024-05-01 |
| A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies cemiplimab, odronextamab - Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 105 | 2016-01-11 | 2026-06-02 |
| Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide - Advanced Cancer, Advanced Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 398 | 2015-02-02 | 2020-01-27 |
Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Colonic Neoplasms (2) · Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1)
Regeneron Pharmaceuticals (6) · Dana-Farber Cancer Institute (2) · Sanofi (2) · EMD Serono Research & Development Institute, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Inimmune Corporation (1) · Palleon Pharmaceuticals, Inc. (1) · Sensei Biotherapeutics, Inc. (1) · SillaJen, Inc. (1)
United States (13) · Australia (7) · South Korea (6) · Spain (5) · United Kingdom (4) · France (3) · Germany (3) · Italy (3) · Netherlands (3) · Belgium (2) · Canada (2) · Austria (1) · Brazil (1) · Czechia (1) · Estonia (1)
Aixa E Soyano Muller, MD (1) · David A Reardon, MD (1) · Glenn J Hanna, MD (1) · Jon L Ruckle (1) · Ron Weitzman, MD (1)
PMID 27879972, PMID 29863979, PMID 32554615, PMID 33224628, PMID 33477979, PMID 33831732, PMID 33942954, PMID 36821617, PMID 38252908, PMID 38898592, PMID 38900987, PMID 39422598
2016 (3), 2015 (2), 2017 (1), 2018 (1), 2023 (1)